Expression and significance of membrane skeleton protein 4.1s in gastric carcinoma

World Chinese Journal of Digestology

Volumn 15, Issue 32, 2007, Pages 3408-3412

  Xu, Jing Jing ^a   Chen, Li Xiang ^a   Zhai, Wen Jie ^a   Feng, Wen Po ^a   Qi, Yuan Ming ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Gastric carcinoma; Immunohistochemistry; Protein 4.1

Indexed keywords

MEMBRANE SKELETON PROTEIN 4.1B; MEMBRANE SKELETON PROTEIN 4.1G; MEMBRANE SKELETON PROTEIN 4.1N; MEMBRANE SKELETON PROTEIN 4.1R; ONCOPROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; STOMACH CARCINOMA; TUMOR DIFFERENTIATION;

EID: 39749139371     PISSN: 10093079     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Diakowski W, Grzybek M, Sikorski AF. Protein 4.1, a component of the erythrocyte membrane skeleton and its related homologue proteins forming the protein 4.1/FERM superfamily. Folia Histochem Cytobiol 2006; 44: 231-248
2. Conboy J, Marchesi S, Kim R, Agre P, Kan YW, Mohandas N. Molecular analysis of insertion/deletion mutations in protein 4.1 in elliptocytosis. II. Determination of molecular genetic origins of rearrangements. J Clin Invest 1990; 86: 524-530
3. Calinisan V, Gravem D, Chen RP, Brittin S, Mohandas N, Lecomte MC, Gascard P. New insights into potential functions for the protein 4.1 superfamily of proteins in kidney epithelium. Front Biosci 2006; 11: 1646-1666
4. Hoover KB, Bryant PJ. The genetics of the protein 4.1 family: organizers of the membrane and cytoskeleton. Curr Opin Cell Biol 2000; 12: 229-234
5. Robb VA, Li W, Gascard P, Perry A, Mohandas N, Gutmann DH. Identification of a third Protein 4.1 tumor suppressor, Protein 4.1R, in meningioma pathogenesis. Neurobiol Dis 2003; 13: 191-202
6. Rajaram V, Gutmann DH, Prasad SK, Mansur DB, Perry A. Alterations of protein 4.1 family members in ependymomas: a study of 84 cases. Mod Pathol 2005; 18: 991-997
7. Kikuchi S, Yamada D, Fukami T, Masuda M, Sakurai-Yageta M, Williams YN, Maruyama T, Asamura H, Matsuno Y, Onizuka M, Murakami Y. Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer. Clin Cancer Res 2005; 11: 2954-2961
8. Kittiniyom K, Mastronardi M, Roemer M, Wells WA, Greenberg ER, Titus-Ernstoff L, Newsham IF. Allele-specific loss of heterozygosity at the DAL-1/4.1B (EPB41L3) tumor-suppressor gene locus in the absence of mutation. Genes Chromosomes Cancer 2004; 40: 190-203
9. Wong SY, Haack H, Kissil JL, Barry M, Bronson RT, Shen SS, Whittaker CA, Crowley D, Hynes RO. Protein 4.1B suppresses prostate cancer progression and metastasis. Proc Natl Acad Sci U S A 2007; 104: 12784-12789
10. Roskams T. The role of immunohistochemistry in diagnosis. Clin Liver Dis 2002; 6: 571-589
11. Anderson C, Nijagal A, Kim J. Molecular markers for gastric adenocarcinoma: an update. Mol Diagn Ther 2006; 10: 345-52
12. Sarbia M, Becker KF, Hofler H. Pathology of upper gastrointestinal malignancies. Semin Oncol 2004; 31: 465-475
13. Chan AO, Lam SK, Chu KM, Lam CM, Kwok E, Leung SY, Yuen ST, Law SY, Hui WM, Lai KC, Wong CY, Hu HC, Lai CL, Wong J. Soluble E-cadherin is a valid prognostic marker in gastric carcinoma. Gut 2001; 48: 808-811
14. Harn HJ, Ho LI, Shyu RY, Yuan JS, Lin FG, Young TH, Liu CA, Tang HS, Lee WH. Soluble CD44 isoforms in serum as potential markers of metastatic gastric carcinoma. J Clin Gastroenterol 1996; 22: 107-110
15. Charboneau AL, Singh V, Yu T, Newsham IF. Suppression of growth and increased cellular attachment after expression of DAL-1 in MCF-7 breast cancer cells. Int J Cancer 2002; 100: 181-188
16. Nunomura W, Takakuwa Y, Tokimitsu R, Krauss SW, Kawashima M, Mohandas N. Regulation of CD44-protein 4.1 interaction by Ca2+ and calmodulin. Implications for modulation of CD44-ankyrin interaction. J Biol Chem 1997; 272: 30322-30338
17. Hiscox S, Jiang WG. Ezrin regulates cell-cell and cell-matrix adhesion, a possible role with E-cadherin/beta-catenin. J Cell Sci 1999; 112 Pt 18: 3081-3090
18. Yageta M, Kuramochi M, Masuda M, Fukami T, Fukuhara H, Maruyama T, Shibuya M, Murakami Y. Direct association of TSLC1 and DAL-1, two distinct tumor suppressor proteins in lung cancer. Cancer Res 2002; 62: 5129-5133
19. Huang SC, Liu ES, Chan SH, Munagala ID, Cho HT, Jagadeeswaran R, Benz EJ Jr. Mitotic regulation of protein 4.1R involves phosphorylation by cdc2 kinase. Mol Biol Cell 2005; 16: 117-127
20. Mattagajasingh SN, Huang SC, Hartenstein JS, Snyder M, Marchesi VT, Benz EJ. A nonerythroid isoform of protein 4.1R interacts with the nuclear mitotic apparatus (NuMA) protein. J Cell Biol 1999; 145: 29-43
21. Perry A, Gutmann DH, Reifenberger G. Molecular pathogenesis of meningiomas. J Neurooncol 2004; 70: 183-202
22. Walensky LD, Gascard P, Fields ME, Blackshaw S, Conboy JG, Mohandas N, Snyder SH. The 13-kD FK506 binding protein, FKBP13, interacts with a novel homologue of the erythrocyte membrane cytoskeletal protein 4.1. J Cell Biol 1998; 141: 143-153
23. Chelu MG, Danila CI, Gilman CP, Hamilton SL. Regulation of ryanodine receptors by FK506 binding proteins. Trends Cardiovasc Med 2004; 14: 227-234
24. Neye H, Verspohl EJ. The FK506 binding protein 13 kDa (FKBP13) interacts with the C-chain of complement C1q. BMC Pharmacol 2004; 4: 19
25. Ye K, Compton DA, Lai MM, Walensky LD, Snyder SH. Protein 4.1N binding to nuclear mitotic apparatus protein in PC12 cells mediates the antiproliferative actions of nerve growth factor. J Neurosci 1999; 19: 10747-10756
26. Zeng C. NuMA: a nuclear protein involved in mitotic centrosome function. Microsc Res Tech 2000; 49: 467-477
27. Ramez M, Blot-Chabaud M, Cluzeaud F, Chanan S, Patterson M, Walensky LD, Marfatia S, Baines AJ, Chasis JA, Conboy JG, Mohandas N, Gascard P. Distinct distribution of specific members of protein 4.1 gene family in the mouse nephron. Kidney Int 2003; 63: 1321-1337
28. Shi ZT, Afzal V, Coller B, Patel D, Chasis JA, Parra M, Lee G, Paszty C, Stevens M, Walensky L, Peters LL, Mohandas N, Rubin E, Conboy JG. Protein 4.1R-deficient mice are viable but have erythroid membrane skeleton abnormalities. J Clin Invest 1999; 103: 331-340
29. Ohno N, Terada N, Yamakawa H, Komada M, Ohara O, Trapp BD, Ohno S. Expression of protein 4.1G in Schwann cells of the peripheral nervous system. J Neurosci Res 2006; 84: 568-577
30. Gutmann DH, Donahoe J, Perry A, Lemke N, Gorse K, Kittiniyom K, Rempel SA, Gutierrez JA, Newsham IF. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet 2000; 9: 1495-1500